Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing

被引:9
|
作者
Lopez, Adriana Gamboa [1 ,2 ]
Allu, Srinivasa Rao [3 ,4 ]
Mendez, Patricia [1 ,2 ]
Reddy, Guddeti Chandrashekar [3 ,4 ]
Maul-Newby, Hannah M. [1 ,2 ]
Ghosh, Arun K. [3 ,4 ]
Jurica, Melissa S. [1 ,2 ]
机构
[1] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA
[2] Univ Calif Santa Cruz, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA
[3] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[4] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
D O I
10.1021/acschembio.0c00965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Small molecules that target the spliceosome SF3B complex are potent inhibitors of cancer cell growth. The compounds affect an early stage of spliceosome assembly when U2 snRNP first engages the branch point sequence of an intron. Employing an inactive herboxidiene analog (iHB) as a competitor, we investigated factors that influence inhibitor interactions with SF3B to interfere with pre-mRNA splicing in vitro. Order-of-addition experiments show that inhibitor interactions are long lasting and affected by both temperature and the presence of ATP. Our data are also consistent with the model that not all SF3B conformations observed in structural studies are conducive to productive inhibitor interactions. Notably, SF3B inhibitors do not impact an ATP-dependent rearrangement in U2 snRNP that exposes the branch binding sequence for base pairing. We also report extended structure-activity relationship analysis of the splicing inhibitor herboxidiene. We identified features of the tetrahydropyran ring that mediate its interactions with SF3B and its ability to interfere with splicing. In the context of recent structures of SF3B bound to inhibitor, our results lead us to extend the model for early spliceosome assembly and inhibitor mechanism. We postulate that interactions between a carboxylic acid substituent of herboxidiene and positively charged SF3B1 side chains in the inhibitor binding channel are needed to maintain inhibitor occupancy while counteracting the SF3B transition to a dosed state that is required for stable U2 snRNP interactions with the intron.
引用
收藏
页码:520 / 528
页数:9
相关论文
共 50 条
  • [31] Splicing factor 3B1 hypomethylation is associated with altered SF3B1 transcript expression in older humans
    Holly, Alice C.
    Pilling, Luke C.
    Hernandez, Dena
    Lee, Benjamin P.
    Singleton, Andrew
    Ferrucci, Luigi
    Melzer, David
    Harries, Lorna W.
    MECHANISMS OF AGEING AND DEVELOPMENT, 2014, 135 : 50 - 56
  • [32] Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization
    Liu, Zhaoqi
    Yoshimi, Akihide
    Wang, Jiguang
    Cho, Hana
    Lee, Stanley Chun-Wei
    Ki, Michelle
    Bitner, Lillian
    Chu, Timothy
    Shah, Harshal
    Liu, Bo
    Mato, Anthony R.
    Ruvolo, Peter
    Fabbri, Giulia
    Pasqualucci, Laura
    Abdel-Wahab, Omar
    Rabadan, Raul
    CANCER DISCOVERY, 2020, 10 (06) : 806 - 821
  • [33] Aberration Of SF3B1 Results In Deregulated Splicing Of Key Genes and Pathways In Myelodysplastic Syndromes
    Dolatshad, Hamid
    Fernandez-Mercado, Marta
    Yip, Bon Ham
    Smith, Chris J.
    Attwood, Martin
    Di Genua, Cristina
    Sahgal, Natasha
    Przychodzen, Bartlomiej P.
    Papaemmanuil, Elli
    Kanapin, Alexander A.
    Lockstone, Helen
    Campbell, Peter J.
    Maciejewski, Jaroslaw P.
    Pellagatti, Andrea
    Boultwood, Jacqueline
    BLOOD, 2013, 122 (21)
  • [34] Targeting SF3B1 mediated splicing control of Mcl-1 in chronic lymphocytic leukemia
    Chen, Rong
    Chen, Yuling
    Ghia, Emanuela M.
    Rassenti, Laura
    Kipps, Thomas
    Keating, Michael J.
    Wierda, William G.
    Plunkett, William
    CANCER RESEARCH, 2014, 74 (19)
  • [35] Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages
    Effenberger, Kerstin A.
    Urabe, Veronica K.
    Prichard, Beth E.
    Ghosh, Arun K.
    Jurica, Melissa S.
    RNA, 2016, 22 (03) : 350 - 359
  • [36] Impact of SF3B1 mutation in myelofibrosis
    Senapati, Jayastu
    Verstovsek, Srdan
    Masarova, Lucia
    Pemmaraju, Naveen
    Patel, Keyur P.
    Montalban-Bravo, Guillermo
    Pierce, Sherry A.
    Zhou, Lingsha
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Bose, Prithviraj
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2701 - 2705
  • [37] SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer
    Maguire, S.
    Leonidou, A.
    Wai, P.
    Marchio, C.
    Ng, C. K. Y.
    Weigelt, B.
    Sapino, A.
    Vincent-Salomon, A.
    Reis-Filho, J. S.
    Natrajan, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 186 - 186
  • [38] Mutations in the RNA Splicing Factor SF3B1 Promote Transformation through MYC Stabilization
    Yoshimi, Akihide
    Liu, Zhaoqi
    Wang Jiguang
    Cho, Hana
    Lee, Stanley C.
    Ki, Michelle
    Bitner, Lillian E.
    Chu, Timothy
    Mato, Anthony R.
    Ruvolo, Peter P.
    Fabbri, Giulia
    Pasqualucci, Laura
    Rabadan, Raul
    Abdel-Wahab, Omar I.
    BLOOD, 2018, 132
  • [39] SF3B1 Mutations in Hematological Malignancies
    Cilloni, Daniela
    Itri, Federico
    Bonuomo, Valentina
    Petiti, Jessica
    CANCERS, 2022, 14 (19)
  • [40] Novel SF3B1 deletion mutations result in aberrant RNA splicing in CLL patients
    Agrawal, Anant A.
    Seiler, Michael
    Brinton, Lindsey
    Mantel, Rose
    Lapalombella, Rosa
    Woyach, Jennifer A.
    Johnson, Amy J.
    Yu, Lihua
    Byrd, John C.
    Smith, Peter G.
    Blachly, James S.
    Buonamici, Silvia
    CANCER RESEARCH, 2017, 77